“This transaction marks a transformational milestone for Instinct Brothers, positioning us to accelerate our global expansion and enhance access to cutting-edge stem cell-based therapies,” said CEO and Group Chairman Tomoki Nagano. “Going public will allow us to scale operations, broaden our clinical footprint, and advance regenerative treatments that redefine health and longevity.”
The company has ambitious plans to expand its clinic model into Malaysia and Indonesia, construct new facilities in Japan, and advance its Cell Processing Center joint venture.
A Strategic SPAC Deal
Nagano will remain at the helm of the combined company after the merger, which is expected to close in Q3 2025, pending approval by Relativity’s stockholders and other customary regulatory hurdles.
Relativity is a special purpose acquisition company (SPAC), also known as a blank check company, designed to raise funds through an IPO to acquire and publicly list private firms.
“Instinct Brothers has built a well-integrated business that translates scientific innovation from the lab to the bedside,” said Relativity CEO Tarek Tabsh. “Their vertically integrated platform—spanning research, manufacturing, distribution, retail, and clinical application—positions them uniquely for expansion into adjacent markets. We are excited to support their journey in delivering the next generation of regenerative medicine.”
